Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89.6M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
61.7M
-
Shares change
-
-1.4M
-
Total reported value, excl. options
-
$1.16B
-
Value change
-
-$20.1M
-
Put/Call ratio
-
1.25
-
Number of buys
-
60
-
Number of sells
-
-55
-
Price
-
$18.75
Significant Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q2 2023
140 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2023.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61.7M shares
of 89.6M outstanding shares and own 68.9% of the company stock.
Largest 10 shareholders include Alphabet Inc. (10.5M shares), FMR LLC (6.05M shares), ARK Investment Management LLC (5.15M shares), VANGUARD GROUP INC (4.09M shares), BlackRock Inc. (3.85M shares), STATE STREET CORP (3.06M shares), FEDERATED HERMES, INC. (2.4M shares), Casdin Capital, LLC (2.36M shares), Nikko Asset Management Americas, Inc. (2.19M shares), and Sumitomo Mitsui Trust Holdings, Inc. (2.19M shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.